Cite
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
MLA
Patrick A Flume, et al. Long-Term Safety and Efficacy of Tezacaftor–ivacaftor in Individuals with Cystic Fibrosis Aged 12 Years or Older Who Are Homozygous or Heterozygous for Phe508del CFTR (EXTEND): An Open-Label Extension Study. July 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bf49af3de3f90b3a65bf102dbba3756b&authtype=sso&custid=ns315887.
APA
Patrick A Flume, Reta Fischer Biner, Damian G Downey, Cynthia Brown, Manu Jain, Rainald Fischer, Kris De Boeck, Gregory S Sawicki, Philip Chang, Hildegarde Paz-Diaz, Jaime L Rubin, Yoojung Yang, Xingdi Hu, David J Pasta, Stefanie J Millar, Daniel Campbell, Xin Wang, Neil Ahluwalia, Caroline A Owen, … Marita Gilljam. (2021). Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Chicago
Patrick A Flume, Reta Fischer Biner, Damian G Downey, Cynthia Brown, Manu Jain, Rainald Fischer, Kris De Boeck, et al. 2021. “Long-Term Safety and Efficacy of Tezacaftor–ivacaftor in Individuals with Cystic Fibrosis Aged 12 Years or Older Who Are Homozygous or Heterozygous for Phe508del CFTR (EXTEND): An Open-Label Extension Study,” July. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....bf49af3de3f90b3a65bf102dbba3756b&authtype=sso&custid=ns315887.